Concepedia

Ken Bartizal

KB

44

Publications

4.2K

Citations

31

H-Index

1984

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Cidara Therapeutics (United States)

United States Military Academy

Arcturus Therapeutics (United States)

University of Wisconsin–Madison

Ken Bartizal is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, microbiology, and antimicrobial resistance.

ORCID

Top concepts

Publications per year

1984–2024

44

Publications

44

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young et al. · Nature · 2006 · 809 citations

, , +11

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Cameron Douglas, Joseph A. D'Ippolito, G.-J. Shei et al. · Antimicrobial Agents and Chemotherapy · 1997 · 336 citations · Full text

, , +16

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

George K. Abruzzo, Amy Flattery, Christopher Gill et al. · Antimicrobial Agents and Chemotherapy · 1997 · 244 citations · Full text

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests

Ana Espinel‐Ingroff, Charles W. Kish, Thomas M. Kerkering et al. · Journal of Clinical Microbiology · 1992 · 244 citations · Full text

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts

Robert A. Fromtling, J N Galgiani, Michael A. Pfaller et al. · Antimicrobial Agents and Chemotherapy · 1993 · 198 citations · Full text

, , +11

Rows per page

1–5 of 44